Novo Nordisk's Amycretin oral weight loss pill demonstrated 13% weight loss in high-dose trials, compared to 1% with a placebo.
Novo Nordisk's oral weight loss pill, Amycretin, has shown promising results in early trials, leading to a 10.4% weight loss at a low dose and over 13% at a higher dose over 12 weeks. This compares favorably to a 1% loss with a placebo. Targeting GLP-1 and amylin hormone receptors, Amycretin may offer a new, more accessible treatment for obesity. Larger trials are underway, with results expected later this year.
September 25, 2024
3 Articles